ReviewTranslational oncology2018
Dendritic Cell-Based Immunotherapy for Solid Tumors.
Review in Translational oncology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 49 citations in OpenAlex.
- Case Report: Primed dendritic cell immunotherapy for multiple solid tumors.Frontiers in immunology · 2026Article
- Lactylation-related risk model for prognostication and therapeutic responsiveness in uterine corpus endometrial carcinoma.Discover oncology · 2025Article
- Engineered immune cell therapies for solid tumors: pharmacological advances, clinical outcomes, and future directions.Frontiers in pharmacology · 2025Review
- Multi-omics cluster defines the subtypes of CRC with distinct prognosis and tumor microenvironment.European journal of medical research · 2024Article
- Trial watch: anticancer vaccination with dendritic cells.Oncoimmunology · 2024Review
- siRNA-Mediated B7H7 Knockdown in Gastric Cancer Lysate-Loaded Dendritic Cells Amplifies Expansion and Cytokine Secretion of Autologous T Cells.Biomedicines · 2023Article
- Implications of IL-21 in solid tumor therapy.Medical oncology (Northwood, London, England) · 2023Review
- Clinical Relevance of Targeted Therapy and Immune-Checkpoint Inhibition in Lung Cancer.Pharmaceutics · 2023Review
- Article
- Features of the immunosuppressive tumor microenvironment in endometrial cancer based on molecular subtype.Frontiers in oncology · 2023Review
- Potential ofOncoimmunology · 2022Article
- Trial watch: Dendritic cell (DC)-based immunotherapy for cancer.Oncoimmunology · 2022Article
- Exosomes: A potential tool for immunotherapy of ovarian cancer.Frontiers in immunology · 2022Review
- Nanotechnology-enhanced immunotherapy for metastatic cancer.Innovation (Cambridge (Mass.)) · 2021Review
- Hyperion Image Analysis Depicts a Preliminary Landscape of Tumor Immune Microenvironment in OSCC with Lymph Node Metastasis.Journal of immunology research · 2021Article
- Article
- Hyperion imaging system reveals heterogeneous tumor microenvironment of oral squamous cell carcinoma patients at T1N0M0 stage.Annals of translational medicine · 2020Article
- Assessment of hazard immune-related genes and tumor immune infiltrations in renal cell carcinoma.American journal of translational research · 2020Article
- Molecular networks of FOXP family: dual biologic functions, interplay with other molecules and clinical implications in cancer progression.Molecular cancer · 2019Review
- Helical tomotherapy for chemo-refractory multiple liver metastases.Cancer medicine · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
As a treatment for solid tumors, dendritic cell (DC)-based immunotherapy has not been as effective as expected. Here, we review the reasons underlying the limitations of DC-based immunotherapy for solid tumors and ask what can be done to improve immune cell-based cancer therapies. Several reports show that, rather than a lack of immune induction, the limited efficacy of DC-based immunotherapy in cases of renal cell carcinoma (RCC) likely results from inhibition of immune responses by tumor-secreted TGF-β and an increase in the number of regulatory T (Treg) cells in and around the solid tumor. Indeed, unlike DC therapy for solid tumors, cytotoxic T lymphocyte (CTL) responses induced by DC therapy inhibit tumor recurrence after surgery; CTL responses also limit tumor metastasis induced by additional tumor-challenge in RCC tumor-bearing mice. Here, we discuss the mechanisms underlying the poor efficacy of DC-based therapy for solid tumors and stress the need for new and improved DC immunotherapies and/or combination therapies with killer cells to treat resistant solid tumors.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.